GBR DOPAMINE TRANSPORTER BINDING:PHARMACOPHORE MODELING

GBR 多巴胺转运蛋白结合：药效团建模

• 批准号: 6546965
• 负责人: KATHLEEN M GILBERT
• 金额: $ 2.78万
• 依托单位: NEW JERSEY INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-24 至 2005-09-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6546965
• 关键词: binding sites; chemical models; chemical structure function; dopamine transporter; drug vehicle; model design /development; molecular dynamics; piperazines; predoctoral investigator

DESCRIPTION (provided by applicant): Cocaine addiction is a problem in the U.S. and around the world. Initial research into the abuse of cocaine revealed its addictive effects on the human body. Cocaine's addictive effects are thought to be related to its binding to several neurotransrnitter transporters, especially the dopamine transporter (DAT) Cocaine is a doparnine reuptake inhibitor which causes less dopamine to be taken up by the DAT. The GBR series of dialkyl piperazines have been identified as selective dopamine uptake inhibitors that could be used to treat cocaine addiction. These compounds have been explored in the laboratory using traditional structure-activity relationship techniques, but pharmacophore development using molecular modeling methods have not been performed on them.The proposed research is a comprehensive molecular modeling study of 300 GBR analogs. The purpose of the study is to identify two pharmacophores: one for the DAT binding site and one for dopamine uptake at the DAT. The pharmacophores will be developed using a Comparative Molecular Field Analysis (CoMFA) study performed in vacuum, and the results refined by repeating the study in solvent. The Partial Least Squares method will be used to model the CoMFA results versus the binding and reuptake data. A bioactive conformer will be selected based on the most predictive model, then used as the basis for the pharmacophores

描述（由申请人提供）：可卡因成瘾是美国和世界各地的一个问题。对可卡因滥用的初步研究表明，可卡因对人体有成瘾作用。可卡因的成瘾作用被认为与它与几种神经递质转运体的结合有关，尤其是多巴胺转运体（DAT） 可卡因是一种多巴酚丁胺再摄取抑制剂，其导致DAT摄取较少的多巴胺。GBR系列二烷基哌嗪已被确定为可用于治疗可卡因成瘾的选择性多巴胺摄取抑制剂。这些化合物已在实验室中探索使用传统的结构-活性关系技术，但药效团的发展，使用分子建模方法还没有进行themes.The拟议的研究是一个全面的300 GBR类似物的分子建模研究。 本研究的目的是确定两个药效团：一个用于DAT结合位点，一个用于DAT的多巴胺摄取。药效团将使用在真空中进行的比较分子场分析（CoMFA）研究开发，并通过在溶剂中重复研究来细化结果。将使用偏最小二乘法对CoMFA结果与结合和再摄取数据进行建模。将基于最具预测性的模型选择生物活性构象异构体，然后用作药效团的基础